Please login to the form below

Not currently logged in
Email:
Password:

Novartis Oncology

This page shows the latest Novartis Oncology news and features for those working in and with pharma, biotech and healthcare.

Boehringer’s Corsico to be new GSK drug dev leader

Boehringer’s Corsico to be new GSK drug dev leader

In addition, GSK’s oncology R&D division, based in Philadelphia, will remain a separate entity, under the oversight of Alex Hoos. ... The most significant of these was the poaching of Luke Miels from AstraZeneca to head up pharma commercial operations,

Latest news

  • Novartis’ CAR-T Kymriah gets green light in England Novartis’ CAR-T Kymriah gets green light in England

    Novartis’oncology manager for the UK and Ireland, Mari Scheiffele, said “flexibility [was] shown by all parties to ensure young patients can access this life-saving treatment as quickly as possible.”. ... That might suggest Novartis will have a

  • Novartis wins key adjuvant Taf/Mek approval in Europe Novartis wins key adjuvant Taf/Mek approval in Europe

    Novartis wins key adjuvant Taf/Mek approval in Europe. Ex-GSK duo on course for first blockbuster year. ... The new indication – the third for the BRAF/MEK inhibitor combination – is an important one for Novartis as it faces increasing competition in

  • Novartis considers filings for PI3K drug in breast cancer Novartis considers filings for PI3K drug in breast cancer

    We… look forward to submitting the data to an upcoming medical congress and starting discussions with health authorities worldwide, ”commented Samit Hirawat, Novartis’head of oncology drug development. ... taselisib candidate alongside fulvestrant

  • Novartis launch NET cancer community app Novartis launch NET cancer community app

    Novartis launch NET cancer community app. Galaxies of Hope aims to provide support to cancer patients. ... Ameet Mallik, executive vice president and head of US oncology at Novartis, said: We believe that this app can have a real, positive impact in the

  • Novartis gets speedy reviews for new Kymriah filings Novartis gets speedy reviews for new Kymriah filings

    Novartis gets speedy reviews for new Kymriah filings. US and EU regulatory agencies will review the drug for DLBCL patients. ... Approval would lead to a sizeable expansion in the eligible patient population for Kymriah, which is a key part of

More from news
Approximately 4 fully matching, plus 104 partially matching documents found.

Latest Intelligence

  • Charting a course for expansion Charting a course for expansion

    Charting a course for expansion. David Meek on Ipsen's strategic pillars and hopes in oncology. ... Doing so was the latest move in a 25-year pharma career that has also encompassed stints at Johnson &Johnson, Novartis - including a spell as its oncology

  • Choosing destiny Choosing destiny

    For instance, if Novo Nordisk designs a secular grail model by combining IBM's Watson with its own therapies, it will be different from, for example, Novartis' secular grail model combining ... immuno-oncology and companion diagnostics.

  • Deal Watch June 2016 Deal Watch June 2016

    Protein engineering - towards enhanced biologics. Also active in immuno-oncology, Novartis signed a broad collaboration and licence agreement with Xencor worth a potential $2.56bn covering two bispecific, tumour targeting antibodies, ... Tiered low

  • Deal Watch May 2016 Deal Watch May 2016

    Not under pressure as are GSK and Pfizer, Novartis announced the separation of its pharmaceuticals division into two business units: Novartis Oncology and Novartis Pharmaceuticals. ... The pharmaceuticals company will include Novartis' other interests in

  • Pharma deals in June 2015 Pharma deals in June 2015

    This was the case following the $20bn asset swap deal announced in April 2014 in which Novartis and GSK swapped vaccine and oncology assets. ... Licence, collaboration. 364. Spinifex Pharmaceuticals/ Novartis. Lead candidate EMA401 - oral treatment for

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • Pfizer’s Elizabeth Barrett joins Novartis as its oncology head Pfizer’s Elizabeth Barrett joins Novartis as its oncology head

    Pfizer’ s Elizabeth Barrett joins Novartis as its oncology head. She succeeds Bruno Strigini who retires. ... Novartis has appointed Elizabeth Barrett to head up its oncology franchise based at the group’s headquarters in Switzerland.

  • Novartis Oncology head Bruno Strigini to retire Novartis Oncology head Bruno Strigini to retire

    Novartis Oncology head Bruno Strigini to retire. Will leave the Swiss pharma firm, and the industry, next year. ... The head of Novartis Oncology Bruno Strigini is set to step down and retire from the pharmaceutical industry.

  • Rainer Boehm and Hervé Hoppenot join Cellectics board Rainer Boehm and Hervé Hoppenot join Cellectics board

    He said: “Despite many advances in oncology, there remains a need to continue to advance the science to meet the needs of its patients. ... Prior to joining Incyte, Hoppenot was the president of Novartis Oncology and has several senior roles with with

  • Alacrita appoints Anna Casse as MD Alacrita appoints Anna Casse as MD

    Prior to BioVault, Casse held several commercial leadership roles including head of Novartis’ophthalmic global business development and licensing, general manager of Novartis’oncology department and she also spent time at

  • Kymab appoints its first chief medical officer Kymab appoints its first chief medical officer

    Kymab appoints its first chief medical officer. Dr Sonia Quaratino joins the firm from Novartis. ... She previous served Novartis as its global clinical programme leader, transitional clinical oncology, with responsibility for the clinical development of

More from appointments
Approximately 1 fully matching, plus 17 partially matching documents found.

Latest from PMHub

  • Igeahub

    Created and curated by Luca Dezzani, MD, Global Medical Director at Novartis Oncology, the Igea blog provides an industry insider’ s view on important topics related to life sciences and healthcare.

  • Marketing strategy in complex environments

    disease. Whilst not new, this approach is becoming increasingly effective for certain therapy areas, particularly  oncology.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics